Common TitleALLY-3
Official Title All-Oral 12-Week Treatment with Daclatasvir plus Sofosbuvir in Patients with Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study
Phase Phase III
ClinicalTrials.gov NCT02032901
Treatments
Daclatasvir
Daclatasvir
Tradename:DaklinzaOther Names:DCVClass:DiscontinuedFunding
IndustryBristol-Myers Squibb